Parkinson's Disease in Latin America & Caribbean
How Parkinson's Disease affects 42 countries in Latin America & Caribbean.
| # | Country | Share (%) |
|---|
Across the 35 countries in Latin America & Caribbean tracked in this dataset, parkinson's disease accounts for an average of 0.8% of total deaths. The regional average of 0.8% is notably higher than the global average of 0.7%, indicating that Latin America & Caribbean carries a disproportionate burden of parkinson's disease mortality relative to the world. In Latin America & Caribbean, parkinson's disease exacts a disproportionate mortality toll, influenced by socioeconomic inequality, uneven healthcare access, and risk factor prevalence that varies markedly between and within countries.
Latin America and the Caribbean have made substantial gains in life expectancy over recent decades, but face growing non-communicable disease burdens, persistent health inequalities, and pockets of high violence-related mortality. Within Latin America & Caribbean, significant variation exists. Virgin Islands (U.S.) records the highest share at 1.5% of total deaths, while Haiti has the lowest at 0.20%. This 1.3 percentage-point spread reflects differences in exposure, health system capacity, demographic structure, and risk factor prevalence across the region. Country-level pages provide detailed mortality breakdowns, time trends, and comparisons for each nation.
No proven primary prevention exists for Parkinson's disease, though epidemiological evidence consistently links physical activity and caffeine consumption to reduced risk. Pesticide regulation and occupational safety standards can reduce environmental exposure. Levodopa remains the gold standard symptomatic treatment, and ensuring its universal availability at affordable cost is critical. Deep brain stimulation improves quality of life in advanced disease. Research into disease-modifying therapies targeting alpha-synuclein aggregation, LRRK2 kinase activity, and glucocerebrosidase function is ongoing.
The mortality estimates presented on this page are derived from the Global Burden of Disease (GBD) study, produced by the Institute for Health Metrics and Evaluation (IHME). The GBD synthesizes data from vital registration systems, verbal autopsies, cancer registries, and surveillance networks across more than 200 countries and territories. Death rates are expressed per 100,000 population and are age-standardized, which adjusts for differences in age structure between populations so that comparisons across countries and over time reflect genuine differences in mortality risk rather than demographic composition.
The dataset typically covers the period from 1990 to 2023, although availability varies by country and cause. When interpreting the figures for parkinson's disease in Latin America & Caribbean, note that higher age-standardized rates indicate a greater mortality burden independent of whether a country's population is older or younger. Trends over time reveal whether public health interventions, economic development, and health system improvements have reduced or increased the toll of this condition in the region.
The cause-of-death categories used on this page follow the Global Burden of Disease cause hierarchy, a standardized classification that groups individual ICD-coded causes into clinically meaningful categories. The "share of deaths" metric shows what percentage of all deaths in a given country or region are attributed to parkinson's disease. A rising share does not necessarily mean more people are dying from this cause — it may reflect success in reducing competing causes of death. Always examine both absolute rates and shares for a complete picture of mortality patterns in Latin America & Caribbean.